Skip to main content
. 2024 Feb 22;18(9):6845–6862. doi: 10.1021/acsnano.3c04471

Figure 4.

Figure 4

Nanoparticle vaccine enhances lymphatic accumulation and uptake by antigen presenting cells. (A) Fluorescent images of vaccine site draining lymph node 6h after subcutaneous injection of vaccine formulated with Cy5-OVAp. (B) Quantification of fluorescence in vaccine site draining lymph node (mean ± SD; n = 5 mice/group; **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons). (C) Percentage of Cy5-OVAp positive cells among immune cell populations in vaccine draining lymph node 6h after injection of vaccine formulated with Cy5-OVAp (mean ± SD; n = 5 mice/group; ***P < 0.001; one-way ANOVA with Tukey’s multiple comparisons). (D) Percentage of Cy5-OVAp positive cells among pDCs and cDCs (cDC1 and cDC2) in the vaccine site draining lymph node 6h after injection of vaccine formulated with Cy5-OVAp (mean ± SD; n = 6–8 mice/group; *P < 0.05, **P < 0.01; unpaired t test).